Revvity Inc
Suletud
SektorTervishoid
99.62 -1.64
Ülevaade
Aktsiahinna muutus
24h
Min
99.23
Max
100.06
Sissetulek | -58M 41M |
|---|---|
Müük | -61M 711M |
P/E Sektori keskmine | 47.293 49.052 |
Aktsiakasum | 1.06 |
Dividenditootlus | 0.27 |
Kasumimarginaal | 5.726 |
Töötajad | 11,000 |
EBITDA | -37M 181M |
Soovitused | Osta |
|---|---|
12 kuu keskmine prognoos | +4.1% upside |
Dividenditootlus Sektori keskmine | 0.27% 2.36% |
|---|---|
Järgmine tulemuste avaldamine | 27. juuli 2026 |
Järgmine dividendimakse kuupäev | 7. aug 2026 |
Järgmine aktsia dividendi kuupäev (ex-date) | 17. juuli 2026 |
Turukapital | 1.3B 11B |
|---|---|
Eelmine avamishind | 101.26 |
Eelmine sulgemishind | 99.62 |
Uudiste sentiment
By Acuity
10%
90%
3 / 342 Pingereas Healthcare
Revvity Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Ettevõttest Revvity Inc
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.